Galapagos NV reports results for the quarter ended in September 30 - Earnings Summary

Lakefront Biotherapeutics NV

31/10/2024 02:31

* Galapagos NV  GLPG.AS  reported a quarterly adjusted loss
of 77
cents​​ per share for the quarter ended September 30, lower than
the same quarter last year, when the company reported EPS of 39
cents.  The mean expectation of two analysts for the quarter was
for a loss of 49 cents per share. Wall Street expected
results to range from -79 cents to -20 cents per share.
    * Revenue fell 50.1% to €59.85 million from a year ago;
analysts
expected €69.44 million. 
    * Galapagos NV's reported EPS for the quarter was a loss
of 77
cents​.
    * The company reported a quarterly loss of $50.43 million.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 155.7% in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for Galapagos NV is
€37.50 
This summary was machine generated from LSEG data October 31 at
02:31 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.49          -0.77          Missed
 Jun. 30 2024      -0.21          0.14           Beat
 Mar. 31 2024      -0.14          1.37           Beat
 Dec. 31 2023      -3.93          2.39           Beat